All Things Afib – Détails, épisodes et analyse

Dr. Thomas Michael Tadros at Brigham and Women's

DECAAF II

Saison 1 · Épisode 17

mardi 6 septembre 2022 • Durée 27:32

Dr. Thomas Michael Tadros returns to the podcast to discuss the DECAAF II Randomized Clinical Trial. As a Board-certified Cardiologist and EP, Dr. Tadros’ gives us the pros and cons and takeaways from this study, that advances AFib knowledge within our specialty.

The study, “Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial” was authored by Marrouche, Wazni, McGann et al and just released in June 2022 by JAMA.

Key points from the paper:

● Question: Among patients with persistent atrial fibrillation (AF), does the addition of magnetic resonance imaging (MRI)-guided fibrosis ablation to conventional catheter ablation affect atrial arrhythmia recurrence?

● Findings: In this randomized clinical trial that included 843 patients with persistent AF, there was no significant difference in atrial arrhythmia recurrence in the MRI-guided fibrosis ablation group compared with the pulmonary vein isolation only group (hazard ratio, 0.95).

● Meaning: Findings do not support the use of MRI-guided fibrosis ablation for the treatment of persistent atrial fibrillation.

All Things Afib is hosted by me, Dr. Armin Kiankhooy. As a board-certified cardiothoracic surgeon, my focus is on advanced treatments for heart and lung failure and minimally-invasive surgical treatments for atrial fibrillation such as the Hybrid Maze procedure. You can find me on staff at Adventist Health Heart and Vascular Institute in St. Helena California.

Discussion points:

● Persistent vs. Paroxysmal Afib and background on the DECAAF I study

● Using MRIs to identify fibrosis prior to ablation

● Follow-up testing showed no differences - 43-46% of patients had a recurrence of AFib

● Patients were all approximately one year out from their diagnosis

● Even in patients with only 7 days of Afib, there was significant fibrosis – due to history of hypertension?

● Interstitial vs. replacement fibrosis

● Stroke incidence and mortality after the procedure

● Epicardial procedures - does this study impact?

● Where do we go with the data from this study? Does it impact practice?

● Scalability of this data/study/impact

● Overall these studies continue to be extremely relevant

Resources:

DECAAF II Study in JAMA

Dr. Brett Gidney LinkedIn

Medicare Cuts!!! (Again???)

Saison 1 · Épisode 16

mardi 16 août 2022 • Durée 50:27

Show Notes - All Things Afib - Episode 17 (16) - Medicare Cuts!!!! with Dr. Brett Gidney

Medicare is slashing reimbursement for AFib procedures during a time of record-setting inflation and an increasing number of patients (currently 6 million) suffering from AFib. From an RVU (Relative Value Unit) of 26.44 in 2021, the payment is being reduced by FORTY PERCENT to 15.88 in 2023. AFib is becoming more and more widespread, in fact, there are predicted to be 20 Million AFib patients by 2050. Afib can often be fixed very easily, REDUCING the burden on the healthcare system, as likelihood of stroke, dementia, and other morbidities are reduced by AFib management.

There are only 1500 EPs in the U.S. right now, and Medicare cuts are actually DE-INCENTIVIZING more doctors from entering this specialty, because they cannot get fairly compensated for their work. Did you know Medicare pays the same amount for an EP to sit in their office and read 3 echocardiograms, as they would get to do a complex AFib procedure/operation?!

Join me and my guest Dr. Brett Gidney to discuss how and why these cuts are happening, and what you can do today to join the fight to reform these Medicare payments.

Dr. Brett Gidney is a cardiac electrophysiologist leading the charge to reform Medicare payments to EPs. He practices throughout the central coast of California from Thousand Oaks up to Santa Maria. He is board certified in clinical cardiac electrophysiology focusing on complex cardiac arrhythmia management. Dr. Gidney spends the majority of his time in the hospital setting performing procedures, such as cardiac ablation, to treat abnormal heart rhythms. He is particularly interested in very low or no radiation exposure facilitated by 3D mapping and ultrasound technologies.

All Things Afib is hosted by me, Dr. Armin Kiankhooy. As a board-certified cardiothoracic surgeon, my focus is on advanced treatments for heart and lung failure and minimally-invasive surgical treatments for atrial fibrillation such as the Hybrid Maze procedure. You can find me on staff at Adventist Health Heart and Vascular Institute in St. Helena California.

Discussion points:

● Dr. Brett Gidney introduction

● The reduction of RVUs– 2021 to 2023 – reduced 40% - bundling/cuts

● EP is a tiny specialty, only 1500 in the US today

● AFib procedures REDUCE the burden on the system

● Who is advocating for these cuts? The RUC and it’s role

● Affect on caseloads/day to day practice

● De-valuing physician services vs. equipment costs

● Will this be the spark that leads to the formation of lobbying groups?

● 501(c)6 vs. 501(c)3

● Reduced access to underserved populations

● The EPAdvocacy.org foundation will soon be up and running

● Reach out to your congressperson and senator, let them know we need reform!

Resources:

Dr. Brett Gidney Twitter

Find Your Representatives

Dr. Bradley Knight LinkedIn

CAST-AF 2022!

Saison 1 · Épisode 15

mercredi 3 août 2022 • Durée 33:09

Show Notes - All Things Afib - CAST-AF 2022 with Dr. Bradley Knight

So many legends in the AFib world are excited about the upcoming Catheter and Surgical Therapies for Atrial Fibrillation (CAST AF) Conference happening at the end of August in Chicago. Here to speak with me about some of the sessions is my esteemed guest Dr. Bradley Knight, Director of Cardiac Electrophysiology, Bluhm Cardiovascular Institute of Northwestern at Northwestern Medicine.

We’ll discuss some of what you’ll see and hear at this world-class conference, happening Friday and Saturday, August 26-27 at the Radisson Blu Aqua in Chicago, IL. The talks scheduled are only 10-15 minutes each, with plenty of time built in for questions and discussion after each section. From AI to PFA, wearables, and other forward-looking AFib topics, presenters and technology, register now to attend and get intense, high-yield information, theories, and technology that you can put into practice the very next day you return to work!

Dr. Knight is the Chester C. and Deborah M. Cooley Distinguished Professor of Cardiology at Northwestern University, and has been the Director of the Heart Rhythm Program at the BCVI, since November 1, 2009. He earned his BS in Public Health/Biostatistics at the University of North Carolina in Chapel Hill, and his MD at the Ohio State University. After completing his training in Medicine, Cardiology, and Cardiac Electrophysiology at the University of Michigan, he joined the Michigan faculty in 1997. He later served as the Director of Cardiac Electrophysiology at the University of Chicago from 2002 to 2009.

As the Medical Director of Cardiac Electrophysiology at Northwestern Medicine, Dr. Knight remains clinically active with a broad range of clinical and research interests in the field of Heart Rhythm Disorders. These interests range from catheter ablation for complex arrhythmias, such as atrial fibrillation, to fundamental issues related to the basic mechanisms of various types of arrhythmias, and the use of imaging in the electrophysiology laboratory to guide ablation procedures and device implantation. He is involved in several multi-center clinical trials that are evaluating novel ablation tools and implantable devices, including the cryoballoon for pulmonary vein isolation, the totally subcutaneous implantable defibrillator, and left atrial appendage occlusion devices. He has coauthored over 300 scientific papers and is on the editorial board of several high-impact medical journals. He has served on the ABIM CCEP Exam Writing Committee for ten years, and is the Editor-in-Chief of the Journal of Cardiovascular Electrophysiology (JCE) and EPLab Digest.

All Things Afib is hosted by me, Dr. Armin Kiankhooy. As a board-certified cardiothoracic surgeon, my focus is on advanced treatments for heart and lung failure and minimally-invasive surgical treatments for atrial fibrillation such as the Hybrid Maze procedure. You can find me on staff at Adventist Health Heart and Vascular Institute in St. Helena California.

Discussion points:

This may be the best conference happening in the world today

Focus on interventional therapies

Structure of the conference, short and intense for high-yield information

The collaborative methods in practice at Northwestern

Hot Topic: Pulse Field Ablation and it’s many advantages

Talking tech: Devices and wearables

The new approaches - using anticoags, closing the left atriral appendage, LAOS III and reducing stroke risks

Training programs at Northwestern – new opportunities

The differences in training from only ten years ago are staggering

Register to attend today!

Resources:

Dr. Bradley Knight Twitter

CATH AF 2022

Dr. T. Jared Bunch LinkedIn

Dementia and Atrial Fibrillation

Saison 1 · Épisode 14

lundi 20 juin 2022 • Durée 53:23

Show Notes - All Things Afib - Episode 15: Dementia and Atrial Fibrillation with Dr. Jared Bunch

As doctors, we often don’t ask our patients (or their spouses) about “memory issues” or other signs of dementia, related to AFib. We usually ask about stroke, clots, and other heart functions but neglect to ask about the brain.

My guest today is Dr. T. Jared Bunch, Head of Section for Heart Rythm Services at the University of Utah. Dr. Bunch specializes in the diagnosis and management of heart rhythm disorders. His current research involves defining mechanisms underlying the association between atrial fibrillation and dementia. He looks at therapeutic opportunities to lower the risk of cognitive decline, the integration of wearable and implantable devices to improve early diagnosis and treatment of arrhythmias, and improving mapping and catheter ablation of arrhythmias.

Dr. Bunch is a section editor for Current Cardiology Risk Reports, Heart Rhythm Journal, and a guest editor for American Heart Journal. He is on the editorial boards of the Heart Rhythm Journal, Journal of Cardiovascular Electrophysiology, Heart, American Heart Journal, JACC electrophysiology, and the Journal of Innovations in Cardiac Rhythm Management. In addition, he is a Professor of Medicine at the University of Utah and Editor-in-chief of the Heart Rhythm Society.

Join us for a discussion on the alarming connection between AFib and dementia, how to manage AFib and also assist in preventing brain decline, and the many exciting studies and trials, books and articles about the relationship between the two.

All Things Afib is hosted by me, Dr. Armin Kiankhooy. As a board-certified cardiothoracic surgeon, my focus is on advanced treatments for heart and lung failure and minimally-invasive surgical treatments for atrial fibrillation such as the Hybrid Maze procedure. You can find me on staff at Adventist Health Heart and Vascular Institute in St. Helena California.

Discussion points:

Dr. T Jared Bunch intro and background

What is dementia? Why should we care about its relation to AFib?

An AFib/Dementia story– the salesman with AFib and “senior moments”

Many times doctors neglect to ask patients about dementia and memory issues – only ask about stroke, clots, etc.

Microbleeds, microclots, and hypoperfusion

Assessing risk through blood panels

The concussion/afib trial

The magnitude of risk for dementia is higher in younger patients – ages 60-70 vs. 70-90

The impact of wearables and the Heartline Trial

Benefits of anticoagulants

Appendage management, AFib, and dementia

CHADS VASC scores and AFib/dementia

What other tests/scores do you look at?

The AFib Cure book and Dr. John Day

Closing words: for anyone listening– Be your own advocate, ask questions, join the AFib online community, and find a doctor who will answer your questions/knows about AFib. There are treatments and ways to address Afib.

Resources:

Dr. Bunch Publications

Join the Heartline Trial/Apple Watch

The Afib Cure Book

StopAFib.org

Dr. Ali Khiabani at Wash U.

Heart Failure and Atrial Fibrillation

Saison 1 · Épisode 13

samedi 28 mai 2022 • Durée 27:31

Show Notes - All Things Afib - Episode 14 - Tachycardia Mediated Cardiomyopathy - Dr. Ali Khiabani from Washington University in St. Louis

Today I’m speaking with Dr. Ali Khiabani, MD, MHA who is currently a fifth-year post-graduate student at Washington University under the tutelage of Dr. Ralph Damiano Jr., one of the world’s leading Cox-Maze surgeons who himself trained under Dr. Cox. Dr. Khiabani and Dr. Damiano have recently co-authored an important paper on the long-term outcomes of the Cox-Maze IV and today we’re going to discuss all the important findings in that paper.

The paper’s abstract reads:

Surgical ablation of atrial fibrillation (AF) is indicated both in patients with AF undergoing concomitant cardiac surgery and in those who have not responded to medical and/or catheter-based ablation therapy. This study examined our long-term outcomes following the Cox-Maze IV procedure (CMP-IV).

And the conclusion states:

The CMP-IV had an excellent long-term efficacy at maintaining sinus rhythm. At late follow-up, the results of the CMP-IV remained superior to those reported for catheter ablation and other forms of surgical ablation for AF. Age, left atrial size, and nonparoxysmal AF were the most relevant predictors of late recurrence.

All Things Afib is hosted by me, Dr. Armin Kiankhooy. As a board-certified cardiothoracic surgeon, my focus is on advanced treatments for heart and lung failure and minimally-invasive surgical treatments for atrial fibrillation such as the Hybrid Maze procedure. You can find me on staff at Adventist Health Heart and Vascular Institute in St. Helena California.

Discussion points:

You have written some impressive papers – can you tell us a little about this paper?

Some important elements in the research:

Patient selection was key

All underwent MRI’s to determine fibrosis levels

37 patients total

Class III or IV EF

Median follow up was 22 mos.

All had significant improvements

It’s not necessary to restore 100% sinus rhythm all the time– what were your statistics?

Any additional points you’d like to share regarding this paper?

Switching gears –tell us about your training with Dr. Damiano

How many procedures until you were comfortable?

What’s next for you with your training or research?

Closing words: for anyone listening– the lesion set in this Bi-Atrial Maze procedure is the most robust method available today for patients with stand-alone AFib

Resources:

Wash U. Article about the Study

Link to Study Abstract

Dr. Thomas Michael Tadros at Brigham and Women's

Early Rhythm Control Therapy - the EAST-AFNET 4 Trial

Saison 1 · Épisode 12

lundi 2 mai 2022 • Durée 30:04

Some high-level takeaways from the paper:

Early initiation of rhythm-control therapy conveys a clear clinical benefit in patients with recently diagnosed atrial fibrillation (AF)

Based on trial results, rhythm-control therapy should be offered to all patients with recently diagnosed AF and cardiovascular risk factors, including those who present without AF-related symptoms, in addition to anticoagulation, rate control, and therapy of concomitant conditions

Early initiation of rhythm-control therapy, before AF-induced atrial damage (atrial cardiopathy or atrial structural remodelling) has irreversibly damaged the atria, could be more effective and safer than the current symptom-based—and therefore delayed—approach to rhythm-control therapy.

All Things Afib is hosted by me, Dr. Armin Kiankhooy. As a board-certified cardiothoracic surgeon, my focus is on advanced treatments for heart and lung failure and minimally-invasive surgical treatments for atrial fibrillation such as the Hybrid Maze procedure. You can find me on staff at Adventist Health Heart and Vascular Institute in St. Helena California.

Discussion points:

What was the purpose and background of this paper?

How realistic is the patient population, compared to your practice?

Figure 1- Meds vs. Ablation, your thoughts?

Is a figure of 20% of patients treated with Amiodarone normal?

What is your opinion on the long-term outcomes in this study?

Afib and cognitive decline/dementia

This study will change how we practice– it’s a game-changer

What protocols do you recommend for your patients that come in earlier and earlier for AFib?

The Mobile Cardiac Telemetry (MCT) monitor vs. others

How smartwatches are raising patient awareness around AFib, and many times are useful tools in cardiac monitoring

Tadros reiterates just how important this study is for all of us

Resources:

The EAST-AFNET 4 Study